TY - JOUR
T1 - Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome
T2 - A pilot study
AU - Dehpouri, Tannaz
AU - Rokni, Ghasem Rahmatpour
AU - Narenjbon, Nematollah Ahangar
AU - Goldust, Mohamad
AU - Yamauchi, Paul S.
AU - Wollina, Uwe
AU - Lotti, Torello
AU - Kircik, Leon
AU - Di Lernia, Vito Giuseppe
AU - Sonthalia, Sidharth
AU - Vojvodic, Aleksandra
AU - Szepietowski, Jacek
AU - Bahadoran, Philippe
AU - Errichetti, Enzo
AU - Cantisani, Carmen
AU - Atzori, Laura
AU - Rezaee, Elham
AU - Kutlubay, Zekayi
AU - Engin, Burhan
AU - Nisticò, Steven
AU - Damiani, Giovanni
AU - Conic, Rosalynn R.Z.
AU - Goren, Andy
AU - Čabrijan, Leo
AU - Tchernev, Georgi
N1 - Publisher Copyright:
©Copyright T. Dehpouri et al., 2019 Licensee PAGEPress, Italy.
PY - 2019
Y1 - 2019
N2 - Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.
AB - Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.
KW - HbA1c
KW - Metabolic syndrome
KW - Methotrexate
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85074564717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074564717&partnerID=8YFLogxK
U2 - 10.4081/dr.2019.7965
DO - 10.4081/dr.2019.7965
M3 - Article
AN - SCOPUS:85074564717
SN - 2036-7392
VL - 11
JO - Dermatology Reports
JF - Dermatology Reports
IS - 1
M1 - 7965
ER -